March 26, 2018
Genentech announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ plus chemotherapy (carboplatin and ABRAXANE) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial treatment of people with advanced squamous non-small cell lung cancer (NSCLC). The study enrolled 1,021 people who were randomized equally (1:1:1) IMpower131 is a Phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of TECENTRIQ in combination with carboplatin and nab-paclitaxel or TECENTRIQ in combination with carboplatin and paclitaxel versus chemotherapy alone in people with stage IV squamous NSCLC. During the treatment-induction phase, people in Arm A received four or six cycles of TECENTRIQ plus carboplatin and paclitaxel, given on day one of each 21-day cycle. During the treatment-induction phase, people in Arm B received four or six cycles of TECENTRIQ, carboplatin and nab-paclitaxel. During the treatment-induction phase, people in Arm C received four or six cycles of carboplatin and nab-paclitaxel. IMpower131 met its PFS co-primary endpoint per study protocol.